Recurate yeon2007

hbp_knowledge/app/yeon2007.bel

@@ -81,70 +81,81 @@ medium (Figs. 2A and 3A). The 50% inhibitory concentrations
 (IC50) of BI-1 were about 1.5 mM for sAPPa and 0.9 mM for APPb,
 respectively. But BI-2, which is mainly composed of the core
 region BACE1 69–73, did not show the inhibitory effects"
-
+#BI - 2 is 69 - 73
+SET Confidence = "Medium"
 p(HGNC:BACE1, frag("67_78")) -| sec(a(HBP:"sAPP-beta"))
 p(HGNC:BACE1, frag("67_78")) -| sec(a(HBP:"sAPP-alpha"))
-p(HGNC:BACE1, frag("69_75")) causesNoChange sec(a(HBP:"sAPP-beta"))
-p(HGNC:BACE1, frag("69_75")) causesNoChange sec(a(HBP:"sAPP-alpha"))
+p(HGNC:BACE1, frag("69_73")) causesNoChange sec(a(HBP:"sAPP-beta"))
+p(HGNC:BACE1, frag("69_73")) causesNoChange sec(a(HBP:"sAPP-alpha"))
+UNSET Confidence
 
 SET Evidence="BI-3 also potentially inhibited the release of sAPPb
 (IC50 = 0.5 mM) and sAPPa (IC50 = 3.4 mM, Figs. 2B and 3B). BI-
 4, which is short peptide of BI-3, showed no effects on sAPP
 secretion."
-
+SET Confidence = "High"
 p(HGNC:BACE1, frag("228_236")) -| sec(a(HBP:"sAPP-beta"))
 p(HGNC:BACE1, frag("228_236")) -| sec(a(HBP:"sAPP-alpha"))
 p(HGNC:BACE1, frag("230_235")) causesNoChange sec(a(HBP:"sAPP-beta"))
 p(HGNC:BACE1, frag("230_235")) causesNoChange sec(a(HBP:"sAPP-alpha"))
+UNSET Confidence
 
 SET Evidence="Surprisingly, BI-1 treatment
 resulted in a drastic, dose-dependent increase in the level
 of intracellular APPa (Figs. 2A and 3A). BI-3 also induced the
 accumulation of intracellular APPa until the concentration
 of BI-3 was raised to 12.5 mM; however, treatment of BI-3
 with 25 mM decreased the level of intracellular APPa."
-
+SET Confidence = "High"
 p(HGNC:BACE1, frag("67_78")) -> a(HBP:"sAPP-alpha", loc(GO:intracellular))
 p(HGNC:BACE1, frag("228_236")) -> a(HBP:"sAPP-alpha", loc(GO:intracellular))
+UNSET Confidence
 
 SET Evidence="Neither, BI-1 nor,
 BI-3, nor any of the other peptides used in this study,
 induced any changes of full-length APP levels. They also did
 not affect the level of b-actin."
-
+#b-actin : ACTB
+SET Confidence = "High"
 p(HGNC:BACE1, frag("67_78")) causesNoChange a(CHEBI:"amyloid-beta")
 p(HGNC:BACE1, frag("69_75")) causesNoChange a(CHEBI:"amyloid-beta")
 p(HGNC:BACE1, frag("228_236")) causesNoChange a(CHEBI:"amyloid-beta")
 p(HGNC:BACE1, frag("230_235")) causesNoChange a(CHEBI:"amyloid-beta")
-
 p(HGNC:BACE1, frag("67_78")) causesNoChange p(HGNC:ACTB)
 p(HGNC:BACE1, frag("69_75")) causesNoChange p(HGNC:ACTB)
 p(HGNC:BACE1, frag("228_236")) causesNoChange p(HGNC:ACTB)
 p(HGNC:BACE1, frag("230_235")) causesNoChange p(HGNC:ACTB)
+UNSET Confidence
 
 SET Evidence="Taken together, these results show that BI-1 and BI-3 not
 only selectively reduce the level of APPbeta but also lead to the
 accumulation of APPalpha in cells with no change of full-length
 APP level."
-
+SET Confidence = "High"
 p(HGNC:BACE1, frag("67_78")) -| a(HBP:"sAPP-beta")
 p(HGNC:BACE1, frag("228_236")) -| a(HBP:"sAPP-beta")
 p(HGNC:BACE1, frag("67_78")) -> a(HBP:"sAPP-alpha")
 p(HGNC:BACE1, frag("228_236")) -> a(HBP:"sAPP-alpha")
+UNSET Confidence
 
 SET Evidence="These results
 suggest that BACE1 derived peptides do not directly inhibit
 BACE activities in vitro when the fluorogenic peptides are used
 as a substrate."
-
+SET Confidence = "Medium"
+p(HGNC:BACE1, frag("69_75")) causesNoChange act(p(HGNC:BACE1))
+p(HGNC:BACE1, frag("230_235")) causesNoChange act(p(HGNC:BACE1))
 p(HGNC:BACE1, frag("228_236")) causesNoChange act(p(HGNC:BACE1))
 p(HGNC:BACE1, frag("67_78")) causesNoChange act(p(HGNC:BACE1))
+UNSET Confidence
 
 SET Evidence="BI-1 treatment
 effectively reduced Ab 40 levels (IC50 = 0.06 mM) in the
 conditioned medium. BI-3 also inhibited Ab 40 production
 (IC50 = 0.2 mM), although the effective concentrations were
 relatively high compared to those of BI-1."
-
+#AB 40 : Amyloid- beta polypeptide 40
+SET Confidence = "High"
 p(HGNC:BACE1, frag("67_78")) -| a(CHEBI:"amyloid-beta polypeptide 40")
 p(HGNC:BACE1, frag("228_236")) -| a(CHEBI:"amyloid-beta polypeptide 40")
+UNSET Confidence